Monotherapy with the Once Weekly Long-Acting GLP-1 Analog LY2189265 for 12 Weeks in Patients with Type 2 Diabetes: Dose-Dependent Effects on Glycemic Control in a Randomized, Double-Blind, Placebo-Controlled Study

被引：0
|
作者：
Grunberger, George
Chang, Anna
Garcia Soria, Martin Gustavo
Botros, Fady T.
Bsharat, Rebhi
Milicevic, Zvonko
机构：
来源：
DIABETES | 2011年 / 60卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1094-P
引用
收藏
页码：A300 / A300
页数：1
相关论文
共 50 条
  • [21] The effects of taurine supplementation on glycemic control and serum lipid profile in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial
    Vahid Maleki
    Mohammad Alizadeh
    Fatemeh Esmaeili
    Reza Mahdavi
    Amino Acids, 2020, 52 : 905 - 914
  • [22] Metabolic efficacy and safety of once-daily pioglitazone monotherapy in patients with type 2 diabetes:: A double-blind, placebo-controlled study
    Scherbaum, WA
    Göke, B
    HORMONE AND METABOLIC RESEARCH, 2002, 34 (10) : 589 - 595
  • [23] The Effects of Soy Protein and Cocoa With or Without Isoflavones on Glycemic Control in Type 2 Diabetes. A Double-Blind, Randomized, Placebo-Controlled Study
    Konya, Judit
    Sathyapalan, Thozhukat
    Kilpatrick, Eric S.
    Atkin, Stephen L.
    FRONTIERS IN ENDOCRINOLOGY, 2019, 10
  • [24] Propolis supplementation improves glycemic and antioxidant status in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled study
    Afsharpour, Fatemeh
    Javadi, Maryam
    Hashemipour, Sima
    Koushan, Yaghob
    Haghighian, Hossein Khadem
    COMPLEMENTARY THERAPIES IN MEDICINE, 2019, 43 : 283 - 288
  • [25] Tolerability, pharmacokinetics and pharmacodynamics of the once-daily human GLP-1 analog liraglutide in Japanese healthy subjects: a randomized, double-blind, placebo-controlled dose-escalation study
    Irie, S.
    Matsumura, Y.
    Zdravkovic, M.
    Jacobsen, L. V.
    Kageyama, S.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2008, 46 (06) : 273 - 279
  • [26] A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Dose Cohort Study to Evaluate the Efficacy and Safety of 12 Once-Weekly Subcutaneous Doses of PB-119 to Patients with Type 2 Diabetes Mellitus as Monotherapy
    Xu, Min
    DIABETES, 2020, 69
  • [27] Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial
    Lennart Tonneijck
    Mark M. Smits
    Marcel H. A. Muskiet
    Trynke Hoekstra
    Mark H. H. Kramer
    A. H. Jan Danser
    Michaela Diamant
    Jaap A. Joles
    Daniël H. van Raalte
    Diabetologia, 2016, 59 : 1412 - 1421
  • [28] Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial
    Tonneijck, Lennart
    Smits, Mark M.
    Muskiet, Marcel H. A.
    Hoekstra, Trynke
    Kramer, Mark H. H.
    Danser, A. H. Jan
    Diamant, Michaela
    Joles, Jaap A.
    van Raalte, Daniel H.
    DIABETOLOGIA, 2016, 59 (07) : 1412 - 1421
  • [29] Exenatide Exhibits Dose-Dependent Effects on Glycemic Control over 12 Weeks in Japanese Patients with Suboptimally Controlled Type 2 Diabetes
    Kadowaki, Takashi
    Namba, Mitsuyoshi
    Yamamura, Ayuko
    Sowa, Hideaki
    Wolka, Anne M.
    Brodows, Robert G.
    ENDOCRINE JOURNAL, 2009, 56 (03) : 415 - 424
  • [30] The influence of chromium chloride containing milk to glycemic control of the patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial
    Kuo, SW
    DIABETOLOGIA, 2005, 48 : A272 - A272
12345